TP53 is mutated in a relatively small population of melanoma cases (17%); in most melanomas nonetheless this pathway is inactivated due to MDM2 or MDM4 amplification, CDKN2A deletion, or deregulation of ASPP. Here, CDKN2A is linked to melanoma.